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OBJECTIVE — Randomized treatment comparing an intensive glycemic treatment strategy
withastandardstrategyintheActiontoControlCardiovascularRiskinDiabetes(ACCORD)trial
was ended early because of an unexpected excess of mortality in the intensive arm. As part of
ongoing post hoc analyses of potential mechanisms for this ﬁnding, we explored whether on-
treatment A1C itself had an independent relationship with mortality.
RESEARCH DESIGN AND METHODS — Participants with type 2 diabetes (n 
10,251 with mean age 62 years, median duration of diabetes 10 years, and median A1C 8.1%)
were randomly assigned to treatment strategies targeting either A1C 6.0% (intensive) or A1C
7.0–7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of
intensive treatment were analyzed using several multivariable models.
RESULTS — Various characteristics of the participants and the study sites at baseline had
signiﬁcant associations with the risk of mortality. Before and after adjustment for these covari-
ates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for
the last interval of follow-up or the decrease of A1C in the ﬁrst year. Higher average A1C was
associated with greater risk of death. The risk of death with the intensive strategy increased
approximately linearly from 6–9% A1C and appeared to be greater with the intensive than with
the standard strategy only when average A1C was 7%.
CONCLUSIONS — These analyses implicate factors associated with persisting higher A1C
levels,ratherthanlowA1Cperse,aslikelycontributorstotheincreasedmortalityriskassociated
with the intensive glycemic treatment strategy in ACCORD.
Diabetes Care 33:983–990, 2010
T
ype 2 diabetes is associated with in-
creasedriskofcardiovascularevents
(1–3) in part because hypertension,
dyslipidemia, and other risk factors are
associatedwithdiabetes.Epidemiological
analyses also suggest that each 1% higher
A1C is associated with 15–20% greater
cardiovascular risk (4–7). The Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) trial was designed to test
whether intensive intervention to control
hyperglycemiatoanearlynormalrangein
patients with type 2 diabetes can reduce
cardiovascular risks (8–10). It also in-
cluded randomized comparisons of two
targets for blood pressure control and two
regimens for control of plasma lipid levels.
The aim of an intensive glycemic
strategy was to reduce A1C to 6.0%,
whereastheaimofastandardstrategywas
foramoreconventionaltargetrange(10).
Because of an unexpected ﬁnding, the in-
tensive treatment strategy was discontin-
ued early, after 3.4 years (median) rather
than the planned 5.6 years of follow-up.
All-cause mortality was greater with the
intensive strategy (1.4 vs. 1.1% per pa-
tient-year[257vs.203totaldeathsduring
follow-up], resulting in a hazard ratio
[HR] of 1.22, P  0.04). Initial analyses
did not identify any speciﬁc cause for this
ﬁnding (11). Several potential mecha-
nisms have been suggested, including hy-
poglycemia, weight gain, and individual
drugs, drug combinations, or drug dos-
ages (12–14). In addition, the effects of
rapid lowering of glucose levels or main-
tenance of nearly normal levels are of
great interest. Although the ACCORD
trial compared treatment strategies rather
than actual levels of A1C, the question
arises whether A1C values 7% may, in-
dependent of other circumstances, pose
an unacceptable risk of death for any
high-risk person with type 2 diabetes. To
clarify this relationship between glycemic
control and mortality, we performed post
hoc analyses using data obtained at base-
line and during randomized treatment.
RESEARCH DESIGN AND
METHODS— The rationale, study
design, and entry criteria for the AC-
CORD trial are described elsewhere (8–
10). The ACCORD trial was conducted at
77 clinical sites in the U.S. and Canada.
BetweenJanuary2001andOctober2005,
10,251 participants with type 2 diabetes
and either a prior cardiovascular event or
other evidence of high risk were enrolled.
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intensive glycemic strategy with the aim
of achieving A1C 6.0% or a standard
strategy with the aim of keeping A1C be-
tween 7.0 and 7.9%. Any antihyperglyce-
mic agents approved by regulatory
authorities could be used, as considered
appropriate for each individual by inves-
tigators at the clinical sites, together with
lifestyle interventions. The ACCORD for-
mulary provided, free of cost to partici-
pants, at least one agent in each of the
major categories of antihyperglycemic
drugs. In addition, in a double two-by-
two factorial design, all participants were
enrolled in either a blood pressure trial
comparing an intensive with a standard
treatment strategy or a lipid trial compar-
ing treatment with fenoﬁbrate versus pla-
cebo while maintaining good control of
LDLcholesterol,mainlywithsimvastatin.
Theprimaryendpointofallcomponentsof
the ACCORD trial is a composite of cardio-
vascular mortality, nonfatal myocardial in-
farction, or nonfatal stroke. All-cause
mortality is a predeﬁned secondary end
point.
The intensive glycemic treatment
strategy was stopped in February 2008.
The dataset used for the present analyses
comprises ﬁndings for all randomized
participantsfromenrollmentuntil10De-
cember 2007. Of the 10,251 participants
in the ACCORD trial, 5,123 were ran-
domly assigned to standard and 5,128 to
intensive glycemic management.
Participants visited clinical sites every
2–4months.Atthe4-monthintervals,they
were asked about hypoglycemia and other
medical events, were weighed, and had
blood collected for A1C measurements.
Statistical analysis
Four ways of assessing each participant’s
glycemic levels were used. First, the over-
all glycemic exposure during randomized
treatment was deﬁned as a time-varying
covariate of the mean of all 4-month A1C
values after the baseline measurement to
theendoftheperiodcoveredinthisdata-
set or until the time of death. This was
called the average A1C. Second, a time-
varying measure reﬂecting glycemic con-
trol just before each measurement was
also used. This was termed the last A1C.
Third, the magnitude of the early reduc-
tion of glucose levels was assessed as a
time-varying covariate by subtracting the
meanofA1Cvaluesintheﬁrst12months
after initiation of glycemic treatment for
each participant from the baseline value.
For the ﬁrst 4 months, the 0- to 4-month
decrease was used, for months 4–8, the
difference between baseline and the aver-
age of 4 and 8 months was used; and for
months 8 and onward the difference be-
tween baseline and the average of months
4, 8, and 12. This was the 1-year decrease
in A1C. Finally, the earliest changes in
A1C were examined by computing 0- to
4-month decreases from baseline. This
was the 4-month decrease in A1C.
Potential confounders of interpreta-
tion of the relationships between time-
varying measures of A1C and occurrence
of mortality from any cause included
characteristics of the participants at base-
line, characteristics of the clinical site at
which an individual was enrolled, and se-
lected factors related to the randomiza-
tion or postrandomization experience
(Table 1). Study site characteristics in-
cluded the number of participants en-
rolled, whether the site was part of an
integrated health plan, whether the prin-
cipal investigator was a diabetes special-
ist, and whether a full-time certiﬁed
diabetes educator was part of the staff.
Postrandomization factors (not shown in
Table 1) included incidence of hypogly-
cemia requiring medical assistance and
weightgainorloss.Hypoglycemiarequir-
ing medical assistance was deﬁned as a
time-varying covariate of self-report of
hypoglycemic symptoms requiring assis-
tancebymedicalpersonnelonatleastone
occasion before death or completion of
the period of treatment. The time-varying
covariate is 0 until a hypoglycemic epi-
sode and 1 thereafter. Weight change
from baseline was deﬁned as a time-
varying covariate and divided into loss of
weight 5 kg, gain of 5 kg, and gain or
loss of up to 5 kg. Factors introduced at
randomization included participation in
the bloodpressureorlipidtrial,assignment
to intensive blood pressure treatment, and
assignment to fenoﬁbrate treatment
(15,16). Inclusion in these treatment
groupsisnotpresentedherebutisincluded
in the modeling procedure.
Unadjustedrelationshipsofthesefac-
tors with all-cause mortality were exam-
ined to identify potentially confounding
variables using Cox proportional hazard
models with Wald conﬁdence intervals
andtests.Factorswithunivariaterelation-
ships with P  0.25 were used in a model
selection procedure. Backwards, for-
wards, and stepwise approaches resulted
in the same models. Baseline A1C was in-
cluded in all models. Model 1 included
the selected characteristics of the partici-
pants and their sites at baseline. Model 2
added severe hypoglycemia and weight
change as time-varying covariates and the
randomization assignments in other AC-
CORD trials. Model 3 included the com-
ponentsofmodel2plusassignmenttothe
standard or intensive glycemic treatment
strategies. Curves modeling the relation-
ships over the range of observed A1C val-
ues (penalized B-splines) (17,18) were
used to explore the linearity assumption
in the Cox proportional hazards model.
Figure 1 presents the linear portion of the
Cox proportional hazards model [xi in
hi(t)  h(t)e
xi). Tests of linearity of the
effect of average A1C were performed by
comparing models with linear terms with
those with spline terms using likelihood
ratio tests. Testing for differences of the
nonlinearﬁtsbetweenintensiveandstan-
dard glycemia assignment was done by
comparing the nested models with one
spline (same for both groups) and two
splines (allowing different ﬁts), also with
likelihood ratio tests. Finally, Poisson re-
gression provided direct estimates of
mortality rates in relation to the magni-
tude of the 1-year change of A1C.
RESULTS
Patterns of glycemic control and
mortality in the intensive and
standard treatment groups
A1C values declined rapidly from the 8.1%
(median)baselineinbothtreatmentgroups
in the 1st year of treatment. With standard
treatment,aplateauvaluecloseto7.5%was
maintained thereafter. With intensive treat-
ment a plateau at 6.4% was established be-
tween 12 and 24 months. All-cause
mortalityrateswereequivalentwiththetwo
strategies in the ﬁrst 2 years, but in the 3rd
year the rate with the intensive strategy was
twice that with the standard strategy (sup-
plementaryFigureA1,availableinanonline
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1278/DC1).
Average on-treatment A1C showed
substantial overlap for individuals in the
two groups (supplementary Figure A2).
With the intensive strategy, average A1C
was 6% at 4.4% of the participants’ vis-
its, between 6.0 and 7.0% at 55.1%,
and 7.0% at 40.5%. With the standard
strategy, corresponding values were 0.2,
9.0,and90.8%.Deathsfrombothcardio-
vascular and noncardiovascular causes
occurred over a wide range of A1C values
with both treatment strategies, with con-
siderable overlap between the strategies.
Approximately half of the deaths were
due to cardiovascular causes (135 of 257
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mortality
Baseline characteristic Value HR (95% CI) P value
Overall P
value
Age (years) 62.2  6.8 1.08 (1.061.09) 0.0001
Female 3,952 (38.6) 0.64 (0.520.78) 0.0001
Race/ethnicity 0.001
African-American 1,952 (19) 0.81 (0.631.03) 0.0821
Hispanic 738 (7.2) 0.71 (0.471.06) 0.09
Other 1,117 (10.9) 0.51 (0.350.74) 0.0004
Non-Hispanic white 6,444 (62.9) 1
Diabetes duration 0.002
6–10 years 2,931 (29.3) 0.88 (0.681.14) 0.3,422
11–15 years 1,958 (19.6) 0.86 (0.641.15) 0.3,041
16 years 2,341 (23.4) 1.33 (1.051.7) 0.0203
5 years 2,776 (27.7) 1
History of cardiovascular disease 3,608 (35.2) 2.07 (1.722.48) 0.0001
Prior myocardial infarction 475 (4.6) 1.44 (0.992.09) 0.0592
Heart failure/congestive heart failure 494 (4.9) 3.18 (2.424.17) 0.0001
Retinal surgery 879 (8.6) 1.67 (1.282.17) 0.0001
Amputation 185 (1.8) 2.64 (1.714.09) 0.0001
Education 0.0028
Less than high school 1,521 (14.8) 1.64 (1.232.19) 0.0007
High school graduate 2,704 (26.4) 1.42 (1.11.85) 0.0079
Some college 3,357 (32.8) 1.18 (0.911.53) 0.218
College graduate or more 2,662 (26) 1
Smoking 0.0001
Former 4,527 (44.2) 1.78 (1.442.21) 0.0001
Current 1,429 (14) 2.13 (1.622.8) 0.0001
Never 4,282 (41.8) 1
Alcohol use 0.0589
1–6 drinks/week 1,975 (19.3) 0.75 (0.590.97) 0.0282
7 drinks/week 470 (4.6) 1.15 (0.761.72) 0.5,065
No drinks/week 7,801 (76.1) 1
Insulin use 3,579 (34.9) 1.4 (1.171.69) 0.0003
ACE inhibitor 5,433 (53) 1.27 (1.051.52) 0.0131
Angiotensin receptor blockers 1,639 (16) 0.79 (0.591.04) 0.0928
Statins 6,363 (62.1) 0.92 (0.761.1) 0.3534
Metformin 6,135 (59.8) 0.84 (0.71.01) 0.0665
Secretagogues 5,273 (51.4) 0.79 (0.660.95) 0.0105
Thiazolidinediones 1,982 (19.3) 0.85 (0.671.09) 0.204
BMI (kg/m
2) 32.2  5.5 1 (0.9841.017) 0.9773
Systolic blood pressure (mmHg) 136.4  17.1 1.003 (0.9971.008) 0.3316
Diastolic blood pressure (mmHg) 74.9  10.7 0.975 (0.9660.984) 0.0001
Visual acuity 0.0001
20/40 2,337 (23.9) 3.36 (2.265) 0.0001
20/20–20/40 5,948 (60.7) 2.16 (1.473.18) 0.0001
20/20 1,510 (15.4) 1
Peripheral neuropathy 4,356 (42.6) 1.83 (1.522.2) 0.0001
Heart rate 72.7  11.8 1 (0.9921.008) 0.9311
Q-T index 101.8  5.2 1.05 (1.031.06) 0.0001
A1C (%) 8.3  1.1 1.04 (0.961.14) 0.3252
Fasting plasma glucose (mg/dl) 175.3  56.2 1 (0.9981.001) 0.6445
LDL (mg/dl) 104.9  33.9 0.998 (0.9951.001) 0.119
HDL (mg/dl) 41.9  11.6 0.988 (0.980.996) 0.0054
Triglycerides (mg/dl) 190.1  148.4 1 (0.9991.001) 0.9412
(continued)
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with the standard strategy).
Characteristics of the participants
and study sites and relationships
with mortality
Table 1 shows the composition of the
study population and the unadjusted re-
lationships between all-cause mortality
and baseline characteristics of the partic-
ipants and their study sites.
Associations between A1C and
mortality without and with
adjustment for characteristics of the
participants and study sites and
selected postrandomization events
Results of the proportional hazards re-
gression models adjusting for the effects
of potentially confounding variables are
summarized in Table 2. Of the three A1C
measures, average A1C had the strongest
association with mortality. A 1% higher
average A1C was associated with HRs of
1.20 (P  0.0002) unadjusted, 1.22 (P 
0.0001) after adjustment for baseline,
site-related,andsomepostrandomization
factors, and 1.45 (P  0.0001) after full
adjustment including adjustment for as-
signment to the standard or intensive
treatment strategy. The last A1C showed
noassociationwithmortalityintheunad-
justed analysis or in models 1 and 2, but
afteradjustmentfortreatmentassignment
in model 3, a signiﬁcant association was
apparent (HR 1.14, P  0.003). No rela-
tionships between the 1-year or 4-month
decreases of A1C from baseline and sub-
sequent mortality were found before ad-
justment for covariates, but model 3
demonstrated a signiﬁcant relationship
for the 1-year change (HR 0.85, P 
0.013). With average and last A1C, a
higher on-treatment A1C value was asso-
ciated with a greater risk of death. The
1-year decrease in A1C analysis in model
3 showed that a greater decrease of A1C
was associated with a lower risk of death.
Adjusted risk of all-cause mortality
over the observed range of average
A1C
The relationship between average A1C
and mortality was examined within the
intensive and standard treatment strate-
gies separately, as well as their interac-
tion, using the fully adjusted regression
model 3. Different relationships were ap-
parent (Pinteraction  0.0007). The HR for
1% higher A1C for the intensive strategy
Table 1—Continued
Baseline characteristic Value HR (95% CI) P value
Overall P
value
Serum creatinine (mg/dl) 0.91  0.23 2.44 (1.723.46) 0.0001
Urinary albumin-to-creatinine ratio (mg/mg) 0.0001
30–300 2,501 (24.6) 1.7 (1.392.09) 0.0001
300 673 (6.6) 2.9 (2.23.81) 0.0001
30 6,998 (68.8) 1
Integrated health plan 4,078 (39.8) 1.39 (1.161.68) 0.0004
Endocrinologist or diabetologist 5,706 (55.7) 0.84 (0.71) 0.0556
Certiﬁed diabetes educator on staff at rand 3,960 (38.6) 0.94 (0.781.14) 0.5429
Site size 0.894
100 1,583 (15.4) 0.94 (0.721.24) 0.6837
100–150 3,049 (29.7) 0.97 (0.781.19) 0.7385
150 5,619 (54.8) 1
Values are means  SD, n (%), or HR (95% CI).
Table 2—HRs (95% CI) from Cox proportional hazard models
Model includes
Association of measures of A1C with all-cause mortality
Unadjusted Model 1 Model 2 Model 3
Model 3,
intensive
Model 3
standard
Interaction
P value*
Average A1C 1.20 (1.09–1.32) 1.20 (1.08–1.33) 1.22 (1.10–1.36) 1.45 (1.3–1.63) 1.66 (1.46–1.89) 1.14 (0.95–1.38)
0.0007 P value 0.0002 0.0008 0.0001 P  0.0001 P  0.0001 0.17
Last A1C 1.06 (0.98–1.15) 1.05 (0.96–1.14) 1.07 (0.98–1.16) 1.14 (1.05–1.25) 1.27 (1.14–1.41) 0.98 (0.86–1.13)
0.0030 P value 0.15 0.28 0.12 0.0026 P  0.0001 0.81
1-year decrease
of A1C 1.02 (0.94–1.10) 0.98 (0.87–1.10) 0.96 (0.86–1.07) 0.85 (0.75–0.97) 0.86 (0.74–1.01) 0.83 (0.71–0.97)
0.66 P value 0.69 0.71 0.46 0.0127 0.06 0.0227
4-month
decrease of
A1C 1.00 (0.92–1.09) 0.98 (0.88–1.09) 0.97 (0.87–1.08) 0.90 (0.79–1.01) 0.92 (0.79–1.07) 0.88 (0.76–1.02)
0.61 P value 0.98 0.74 0.56 0.07 0.25 0.07
Model 1 contains these baseline characteristics: age, sex, congestive heart failure, amputation, smoking, alcohol use, use of secretagogues, visual acuity, peripheral
nerve function, Q-T interval, A1C, urinary albumin-to-creatinine ratio, and site in integrated health system. Model 2 adds assignment to blood pressure or lipid trial
and treatment assignment within these, severe hypoglycemia, and weight change. Model 3 adds glycemic treatment strategy assignment. *P value for interaction of
treatment assignment with the A1C relationships in model 3 is shown in the column at the right.
A1C and mortality in ACCORD
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0.0001) and that for the standard strategy
was 1.14 (0.95–1.38, P  0.17). These
relationships for the two strategies were
also examined over a wide range of up-
dated average A1C values, using
smoothed spline plots and adjusting for
all covariates (Fig. 1). These curves were
also clearly different for the two strategies
(Pinteraction  0.0003). There was mar-
ginal evidence of nonlinearity among in-
tensive treatment participants (P  0.08)
but stronger evidence for nonlinearity
among standard treatment participants
(P  0.0184). The curve for the intensive
strategy showed the risk of mortality in-
creasingsteadilywithhigheraverageA1C
intherangefrom6.0to9.0%.Incontrast,
the lowest risk with the standard strategy
wasassociatedwithaverageA1Cbetween
7.0and8.0%.Theestimatesforthesetwo
curves were separated for A1C values
from 7.0% to 9.0%, suggesting a possi-
ble higher risk for participants using the
intensive strategy in this range. This ob-
servation is consistent with the increased
riskofmortalityassociatedwiththeinten-
sive strategy using model 3, both without
inclusion of average A1C as a covariate
(HR 1.25, P  0.02) and when average
A1C was included (HR 1.82, P 
0.0001).
Frequency of all-cause mortality
over the range of decrease of A1C in
the 1st year
The effect of the initial decrease in A1C
wasfurtherexploredinananalysisshown
in Fig. 2, which adjusted for the variables
in model 3. With the standard strategy,
death rates during the entire period of
studydidnotvaryovertherangeof1-year
A1C decrease. With the intensive strat-
egy, the risk of death was similar to that
with the standard strategy when moder-
ate or large decreases in A1C occurred,
but higher risk was suggested when little
or no decrease in A1C followed initiation
of treatment.
CONCLUSIONS— These post hoc
analyses produced several hypothesis-
generating insights. First, the 1- to 2-year
delaybetweentheinitialreductionofA1C
and the increase of mortality with the in-
tensivestrategysuggeststhatfactorsother
than current A1C levels contributed. The
broad range of average A1C values before
deaths in both treatment groups also sup-
ports this view.
Second, the glycemic measure most
stronglyassociatedwithdeathwastheav-
erage A1C. Without adjustment, after ad-
justment for baseline factors, and after
furtheradjustmentforsomepostrandom-
ization factors, a 1% greater average A1C
was associated with 20, 20, and 22% in-
creases in the risk of death. This associa-
tion, not taking into consideration the
glycemic treatment strategy, is similar to
the 12 and 14% increments of mortality
associatedwith1%higheraverageA1Cin
epidemiologic analyses from other stud-
ies (6,19). In the fully adjusted analysis
includingglycemictreatmentstrategythis
association was even stronger. Last A1C
measurements and decreases in A1C in
the 1st year of treatment showed weaker
Figure1—Splinecurvesdisplayingtheriskofall-causemortalitywiththetwotreatmentstrategiesovertherangeofaverageA1Cfrom6.0to9.0%.
The curves represent the linear part of the proportional hazards models derived from values for intervals of average A1C from model 3. For clarity,
theﬁgureomitsvalues6and9%;	5%ofdeathsareexcludedfromthisplotatthelowerendandalsoatthehigherendoftheA1Crange,butthese
data are included in the models. The bold orange line represents the intensive treatment strategy group, the bold blue line represents the standard
group, and the ﬁner colored lines represent the 95% CIs for each group.
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after adjustment for treatment assign-
ment. A 1% higher last A1C was associ-
ated with 14% greater risk, and a 1%
greater decrease in A1C from baseline in
the 1st year with 15% lower risk.
Third, the relationships between av-
erageA1Candmortalitydifferedbetween
the treatment strategies. Using the fully
adjusted proportional hazards regression
model, higher average A1C during use of
the intensive strategy was strongly associ-
ated with greater mortality (66% greater
for 1% higher, P  0.0001). To better
understand possible differences intro-
duced by treatment assignment, we also
considered these relationships when dis-
played as smoothed spline plots over a
range of average A1C.
Withtheintensivestrategy,theriskof
death increased continuously from 6.0 to
9.0% average A1C, whereas the curve for
the standard strategy was distinctly non-
linear. The excess risk associated with in-
tensive glycemic treatment occurred
among those participants whose average
A1C,contrarytotheintentofthestrategy,
was 7%.
These observations must be inter-
preted cautiously, because the analyses
were not deﬁned before treatment was
started, the period of follow-up was
shorter than planned, and the results
could have been inﬂuenced by many pos-
trandomization factors. However, they
arerelevanttothedebateaboutwhichtar-
gets for glycemic control should be ad-
visedforpatientswithtype2diabetesand
evidence of high cardiovascular risk.
These ﬁndings conﬁrm the earlier report
warning of increased risk of death associ-
ated with the intensive treatment strategy
in ACCORD (11), but they suggest that
low A1C is unlikely to be a primary me-
diator of this risk. They do not support
thehypothesisthatoverlyrapidreduction
of A1C from high levels increases risk of
death. In fact, the opposite relationship
was observed. Participants who were
unable to reduce A1C after initiation of
the intensive strategy and continued to
have average A1C 7% seemed to be at
greater risk than those with average
A1C 7% using the same strategy or
than those with A1C 7% using a stan-
dard strategy.
At present, the factors that lead to in-
creased risk associated with A1C averag-
ing 7% during use of an intensive
treatment strategy remain unknown.
Characteristics of the participants that
were not measured may be involved.
Amongthesearebehavioralissuessuchas
lack of adherence to medical advice, de-
pression or other psychiatric conditions,
abnormal cognitive function, and social
or ﬁnancial crises. Emergence of serious
medical problems other than diabetes it-
self might interfere with treatment of hy-
perglycemiaandatthesametimeincrease
theriskofmortality.Finally,thepotential
effects of hypoglycemia, weight gain, and
various drugs require further attention.
We also await data on ocular, renal, and
cognitive function, as well as on mortality
and cardiovascular events during longer
follow-up, which may contribute to the
balance of risks versus beneﬁts.
Figure2—Curvesdisplayingall-causemortalityratesbytreatmentforthewholeperiodoffollow-up,overarangeofdecreasesinA1Cfrombaseline
in the 1st year of treatment (as a percentage of A1C). The ﬁgure omits values 5th and 95th percentiles of A1C changes. The full range of values
wasfrom6.8(anincrease)to7.4%(adecrease)frombaseline.ThecalculationsusedaPoissonregressionmodelwithdatafrommodel3.Thebold
orange line represents the intensive treatment group, the bold blue line represents the standard group, and the ﬁner colored lines represent the 95%
CIs for each group.
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that excess risk of all-cause mortality was
associated with the intensive glycemic
treatment strategy used in the ACCORD
trial. They suggest that factors associated
with A1C persisting at 7%, rather than
lower A1C, were associated with this risk.
They are also consistent with other epide-
miologicalanalyses,whichsuggestacontin-
uousgradientofriskofmortality,increasing
from lower to higher A1C levels.
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